Avicenna Therapeutics

Avicenna Therapeutics is a biotechnology company focused on developing a novel class of "enhanced NSAIDs" for the treatment of cancer and inflammatory diseases. The company's lead candidate, NBS-1120, is a dual nitric oxide (NO) and hydrogen sulfide (H2S) releasing derivative of aspirin designed to target tumor inflammatory pathways while significantly reducing gastrointestinal toxicity. By leveraging the therapeutic properties of gaseous signaling molecules, Avicenna aims to improve the efficacy and safety profile of traditional anti-inflammatory agents in oncology settings. The company is currently in the pre-clinical stage, with research demonstrating potent anti-cancer activity and protective effects against NSAID-induced gastric injury.